

## 42 C.F.R. § 12.1

---

### Temporary extension of certain COVID-19 telemedicine flexibilities for prescription of controlled medications.

---

- (a) This section is in effect until the end of the day December 31, 2024. The authorization granted in paragraph (c) of this section expires at the end of December 31, 2024.
- (b) For purposes of this section, a practitioner and a patient have a telemedicine relationship established via COVID-19 telemedicine prescribing flexibilities if:
- (1) The practitioner has not conducted an in-person medical evaluation of the patient; and
  - (2) The practitioner has prescribed one or more controlled substances to the patient
- (i) Pursuant to the designation on March 16, 2020, by the Secretary of Health and Human Services, with concurrence of the Acting DEA Administrator, that the telemedicine allowance under 21 U.S.C. 802(54)(D) applies to all schedule II-V controlled substances in all areas of the United States for the duration of the nationwide public health emergency declared by the Secretary of Health and Human Services on January 31, 2020, as a result of the Coronavirus Disease 2019 pursuant to the authority under section 319 of the Public Health Service Act (42 U.S.C. 247); or

This document is only available to subscribers. Please log in or purchase access.

[Purchase Login](#)